http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Keam, Bhumsuk,Im, Seock-Ah,Koh, Youngil,Han, Sae-Won,Oh, Do-Youn,Cho, Nariya,Kim, Jee Hyun,Han, Wonshik,Kang, Keon Wook,Moon, Woo Kyung,Kim, Tae-You,Park, In Ae,Noh, Dong-Young,Chung, June-Key,Bang, Y Maruzen Co 2013 Breast cancer Vol.20 No.2
<P>The purpose of this study was to determine the usefulness of sequential FDG PET/CTs for prediction of axillary lymph node (ALN) status after neoadjuvant chemotherapy (NAC).</P>
In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer.
Keam, Bhumsuk,Kim, Soyeon,Ahn, Yong-Oon,Kim, Tae Min,Lee, Se-Hoon,Kim, Dong-Wan,Heo, Dae Seog Potamitis Press 2015 Anticancer research Vol.35 No.1
<P>The purpose of the present study was to explore the antiproliferative effect of BYL719, a specific inhibitor for phosphatidylinositol 3-kinase (PI3K) p110α, in human head and neck cancer cell lines, as a single agent or in combination with the irreversible EGFR tyrosine kinase inhibitor, dacomitinib.</P>
Clinical usefulness of AJCC response criteria for neoadjuvant chemotherapy in breast cancer.
Keam, Bhumsuk,Im, Seock-Ah,Lim, Yoojoo,Han, Sae-Won,Moon, Hyeong-Gon,Oh, Do-Youn,Cho, Nariya,Lee, Se-Hoon,Han, Wonshik,Moon, Woo Kyung,Kim, Dong-Wan,Kim, Tae-You,Park, In Ae,Noh, Dong-Young Raven Press 2013 Annals of Surgical Oncology Vol.20 No.7
<P>Recently, the American Joint Committee on Cancer (AJCC) 7th edition proposed new response criteria for neoadjuvant chemotherapy (NAC) in breast cancer. The purpose of this study was to evaluate the clinical usefulness of AJCC response criteria.</P>
Dowook Kim(Dowook Kim),Bhumsuk Keam(Bhumsuk Keam),Soon-Hyun Ahn(Soon-Hyun Ahn),Chang Heon Choi(Chang Heon Choi),Hong-Gyun Wu(Hong-Gyun Wu) 대한방사선종양학회 2022 Radiation Oncology Journal Vol.40 No.4
Purpose: Nasopharyngeal cancer (NPC) has a higher prevalence of regional nodal metastasis than other head and neck cancers; however, level IB lymph node involvement is rare. We evaluated the safety and feasibility of level IB-sparing radiotherapy (RT) for NPC patients. Materials and Methods: We retrospectively reviewed 236 patients with NPC who underwent definitive intensity-modulated RT with or without chemotherapy between 2004 and 2018. Of them, 212 received IB-sparing RT, and 24 received non-IB-sparing RT. We conducted a propensity score matching analysis to compare treatment outcomes according to IB-sparing status. In addition, dosimetric analysis of the salivary glands was performed to identify the relationship between xerostomia and the IB-sparing RT. Results: The median follow-up duration was 78 months (range, 7 to 194 months). Local, regional, and distant recurrences were observed in 11.9%, 6.8%, and 16.1% of patients, respectively. Of the 16 patients with regional recurrence, 14 underwent IB-sparing RT. The most common site categorization of regional recurrence was level II (75%), followed by retropharyngeal lymph nodes (43.8%); however, there was no recurrence at level IB. In the matched cohorts, IB-sparing RT was not significantly related to treatment outcomes. However, IB-sparing RT patients received a significantly lower mean ipsilateral and contralateral submandibular glands doses (all, p < 0.001) and had a lower incidence of chronic xerostomia compared with non-IB-sparing RT patients (p = 0.006). Conclusion: Our results demonstrated that IB-sparing RT is sufficiently safe and feasible for treating NPC. To reduce the occurrence of xerostomia, IB-sparing RT should be considered without compromising target coverage.
Tae Hyun Kim(Tae Hyun Kim),Jin Ho Kim(Jin Ho Kim),Chang Hyun Kang(Chang Hyun Kang),Bhumsuk Keam(Bhumsuk Keam),Hak Jae Kim(Hak Jae Kim) 대한방사선종양학회 2024 Radiation Oncology Journal Vol.42 No.1
Although Fanconi anemia patients accompany a high risk of multiple cancers, radiation therapy on these patients has been carried out only in limited cases due to the concern for radiation toxicity that stems from their susceptibility to radiation. We report a case of a 28-year-old female patient diagnosed as synchronous esophageal and tongue cancer, and underwent two cycles of radiation therapy, inevitably in the condition of coronavirus disease 2019 infection. She received radiation therapy of 30 Gy to esophageal mass with neoadjuvant aim in her first-round radiation therapy, and later received 27 Gy to tongue cancer surgical bed with adjuvant aim in her second-round radiation therapy. With no further treatment, she has been maintaining no evidence of disease state for 7 months. Managing Fanconi anemia patients with multiple cancers using radiation therapy is feasible, in which cases a dose de-escalation may be important considering the radiation toxicity and possible future re-treatment.
Role of concurrent chemoradiation on locally advanced unresectable adenoid cystic carcinoma
( Hyerim Ha ),( Bhumsuk Keam ),( Chan-young Ock ),( Tae Min Kim ),( Jin Ho Kim ),( Eun-jae Chung ),( Seong Keun Kwon ),( Soon-hyun Ahn ),( Hong-gyun Wu ),( Myung-whun Sung ),( Dae Seog Heo ) 대한내과학회 2021 The Korean Journal of Internal Medicine Vol.36 No.1
Background/Aims: Adenoid cystic carcinoma (ACC) is a rare salivary gland tumor characterized by indolence, with a high rate of local recurrence and distant metastasis. This study aimed to investigate the effect of concurrent chemoradiation (CCRT) on locally advanced unresectable ACC. Methods: We retrospectively analyzed clinical data from 10 patients with pathologically confirmed ACC of the head and neck who received CCRT with cisplatin in Seoul National University Hospital between 2013 and 2018. Results: Ten patients with unresectable disease at the time of diagnosis or with positive margins after surgical resection received CCRT with weekly cisplatin. Eight patients (80%) achieved complete remission, of which three later developed distant metastases without local relapse; one patient developed distant metastasis and local relapse. Two patient achieved partial remission without progression. Patients experienced several toxicities, including dry mouth, radiation dermatitis, nausea, and salivary gland inflammation of mostly grade 1 to 2. Only one patient showed grade 3 oral mucositis. Median relapse-free survival was 34.5 months (95% confidence interval, 22.8 months to not reached). Conclusions: CCRT with cisplatin is effective for local control of ACC with manageable toxicity and may be an effective treatment option for locally advanced unresectable ACC.